Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT218 versus Xyrem relative bioavailability crossover study in healthy volunteers
NL-OMON44321Active, not recruiting
- Sponsor
- Avadel Pharmaceuticals
- Start
- Nov 2017
- Modality
- Small Molecules, Cell Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of AV001 and sodium oxybate in narcolepsy (2 arms), sponsored by Avadel Pharmaceuticals. Primary endpoint: Pharmacokinetics and relative bioavailability. Started Nov 2017; status: active, not recruiting.
02
Drugs
AV001sodium oxybate
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NL-OMON44321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44321.